← All trials
NCT05937750
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 3, 2023
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2028
- First posted
- Jul 10, 2023
- Last posted
- Jul 19, 2023
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HansaBioMedLead sponsor
- HansaBioMedStudy director
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.